Amarin Corp Plc (AMRN)

[Laurent Maldague]

Jasb, yes the bottom line is that it's all about slowing the rate of cognitive decline, ideally to a rate matching those without Alzeimers disease. That is the endgame.

But when we're talking about screening for therapies that could potentially achieve the above, especially in short duration trial, you have to be open to the possibility that drugs that improve outcomes in the near term (whether that's scores on cognitive tests or cerebral blood flow) will be good candidates to achieve the ultimate goal stated above.

Here was the result from a recent clinical trial involving EPA rich oil vs DHA rich oil (and vs Olive Oil). We actually see an improvement in cognition over 6 months. The hope is that signal translates into slowing cognitive decline in the long run.


If BRAVE was supposed to succeed based solely on slowing the rate of decline, then it was badly underpowered (both duration and sample size).